Aflibercept's Mechanism in VEGFR Inhibition

How does aflibercept inhibit VEGF receptor (VEGFR-1/VEGFR-2) activation in retinal disease?

Aflibercept inhibits VEGFR-1 and VEGFR-2 activation in retinal disease by binding VEGF-A, VEGF-B, and PlGF with subpicomolar to picomolar affinity, forming 1:1 complexes that sequester these ligands and prevent their engagement with cognate receptors, while also occluding the heparin-binding site on VEGF to block alternative activation pathways.

Abstract

Aflibercept inhibits VEGFR-1 and VEGFR-2 activation in retinal disease primarily through high-affinity sequestration of VEGF family ligands, binding VEGF-A with subpicomolar affinity (KD = 0.490 pM) and blocking receptor activation with IC50 values of 15-26 pM. Unlike antibody-based therapies, aflibercept forms a 1:1 complex with VEGF dimers and uniquely occludes both the receptor-binding sites and heparin-binding site on VEGF165, preventing receptor engagement while exhibiting orders of magnitude faster association rates than bevacizumab or ranibizumab. This canonical mechanism translates to potent inhibition of downstream signaling including calcium mobilization, endothelial cell migration and proliferation, and restoration of barrier function across multiple retinal disease models. Aflibercept’s broader ligand specificity encompasses VEGF-B and PlGF in addition to VEGF-A, enabling inhibition of VEGFR1-mediated pathways in immune cells that contribute to choroidal neovascularization.

Beyond direct VEGFR inhibition, aflibercept operates through context-dependent non-canonical mechanisms. In proliferative diabetic retinopathy, it binds galectin-1 (KD = 23.68 nM), neutralizing an angiogenic factor that activates VEGFR2 independently of VEGF-A. In proliferative vitreoretinopathy, aflibercept’s therapeutic efficacy derives from blocking VEGF’s non-canonical activation of PDGFRα rather than VEGFRs themselves. However, VEGF/KDR inhibition triggers compensatory HIF-1α accumulation and subsequent ANGPTL4 upregulation, a countertherapeutic effect that may limit responses in neovascular age-related macular degeneration. The drug also indirectly suppresses angiopoietin-2 expression, contributing to reduced vascular permeability. These multiple mechanisms explain aflibercept’s efficacy across diverse retinal vascular diseases while identifying HIF-1α pathway activation as a potential resistance mechanism requiring combination therapeutic approaches.

Methods

We analyzed 10 sources from an initial pool of 200, using 7 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.

Records from Elicit search

• n = 200
  Papers screened using: Retinal Disease Population, Aflibercept Intervention, VEGF Receptor Mechanisms, Mechanistic Assessments, Study Design and Sample Size, Mechanistic Data Inclusion, Aflibercept-Specific Effects

• n = 200
  Papers screened out

• n = 190
  Papers included for extraction

• n = 10

Data extraction

We asked a large language model to extract each data column below from each paper.

Target Binding Properties

• Specific ligands bound (VEGF-A, PlGF, VEGF-B, specific isoforms)
• Binding affinity values (KD, IC50, etc.)
• Binding kinetics (association/dissociation rates)
• Binding stoichiometry (1:1, 2:1, etc.)
• Binding specificity compared to natural VEGF receptors
• Any structural details about how binding occurs

VEGFR Inhibition Mechanisms

• Direct effects on VEGFR-1 phosphorylation/activation
• Direct effects on VEGFR-2 phosphorylation/activation
• Downstream signaling pathway effects (calcium mobilization, migration, proliferation)
• Quantitative measures of inhibition (IC50, percentage inhibition)
• Time course of inhibition effects
• Dose-response relationships for VEGFR inhibition

Retinal Cell Effects

• Effects on retinal endothelial cells (migration, proliferation, tube formation)
• Effects on retinal pigment epithelium (RPE) cells
• Effects on immune cells/mononuclear phagocytes in retinal contexts
• Effects on pericytes or other retinal cell types
• Functional outcomes (angiogenesis, vascular leak, inflammation)
• Quantitative measures of cellular responses

Retinal Disease Context

• Type of retinal disease (AMD, diabetic retinopathy, PVR, CNV, etc.)
• Disease model used (animal model, human tissue, cell culture)
• Clinical or experimental outcomes measured
• Efficacy measures specific to retinal disease progression
• Safety findings in retinal contexts
• Biomarkers of disease activity affected

Mechanistic Comparisons

• Direct comparisons to ranibizumab, bevacizumab, or other agents
• Differences in binding properties, potency, or duration
• Differences in VEGFR-1 vs VEGFR-2 selectivity
• Differences in cellular or functional outcomes
• Unique mechanistic advantages or disadvantages
• Head-to-head efficacy comparisons in retinal models

Alternative Mechanisms

• Binding to non-VEGF targets (galectin-1, other proteins)
• Effects on non-VEGF receptors (PDGFR-alpha, etc.)
• Immune complex formation or Fc-mediated effects
• Effects on extracellular matrix or heparin binding
• Indirect pathways affected (inflammatory, immune)
• Any mechanisms independent of VEGF/PlGF binding

Results

Target Binding Properties

Aflibercept demonstrated distinct binding characteristics across VEGF family ligands. The drug bound all isoforms of human VEGF-A with subpicomolar affinity (KD = 0.490 pM), substantially tighter than natural VEGF receptors. Beyond VEGF-A, aflibercept bound human PlGF-2 with KD = 38.9 pM and murine PlGF-2 with KD = 3.32 pM, as well as VEGF-B. The association rate for VEGF-A binding was orders of magnitude faster than that measured for bevacizumab and ranibizumab.

A critical structural feature distinguishing aflibercept from antibody-based therapies was its 1:1 binding stoichiometry with VEGF dimers. This monomeric complex formation contrasted sharply with bevacizumab, which formed multimeric complexes. Aflibercept’s binding mechanism blocked not only the amino acids necessary for VEGFR1/R2 binding but also occluded the heparin-binding site on VEGF165, preventing enhanced binding to heparin or neuropilin.

The drug’s structure comprised the second Ig domain of VEGFR1 and third Ig domain of VEGFR2 fused to human IgG1 Fc region, creating a recombinant fusion protein that bound specifically to VEGF, VEGF-B, and PlGF. This composition enabled aflibercept to mimic natural receptor binding sites while achieving superior affinity.

VEGFR Inhibition Mechanisms

Direct Receptor Inhibition

Aflibercept inhibited both VEGFR1 and VEGFR2 activation through high-affinity ligand sequestration. For VEGF-A121, aflibercept blocked VEGFR1 activation with IC50 = 15 pM and VEGFR2 activation with IC50 = 16 pM. For VEGF-A165, the IC50 values were 16 pM for VEGFR1 and 26 pM for VEGFR2. These inhibition potencies were substantially more potent than ranibizumab or bevacizumab.

In retinal microvascular endothelial cells, aflibercept eliminated galectin-1-induced VEGFR2 phosphorylation, demonstrating direct effects on receptor activation beyond VEGF-A blockade. The drug’s mechanism involved sequestering VEGF, VEGF-B, and PlGF, thereby reducing signaling through VEGF receptors.

Downstream Signaling Effects

Aflibercept’s VEGFR inhibition produced multiple downstream effects on endothelial cell function. The drug inhibited VEGF-A-induced calcium mobilization and cell migration more potently than ranibizumab or bevacizumab. In bovine retinal endothelial cells, aflibercept at therapeutically achievable concentrations reduced VEGF-A-stimulated migration not only to normal values but below basal levels, though this effect was not entirely specific at higher concentrations.

The drug restored and prevented VEGF-A-induced disturbance of the retinal endothelial barrier at ≤25 μg/ml, as measured by transendothelial resistance and claudin-1 expression. Importantly, these therapeutic concentrations did not interfere with normal barrier function. Aflibercept specifically inhibited proliferation stimulated by VEGF-A, PlGF, or combinations of these factors, blocking the proliferative response that drives pathological angiogenesis.

Effects on Retinal Cell Types

Functional Outcomes Across Retinal Disease Models

Comparative Mechanistic Analysis

The evidence reveals that aflibercept operates through both direct VEGFR inhibition and several non-canonical pathways that may contribute to its therapeutic efficacy in retinal disease.

Direct VEGFR Inhibition as the Primary Mechanism

The predominant mechanism involves high-affinity sequestration of VEGF family ligands (VEGF-A, VEGF-B, PlGF), preventing their interaction with VEGFR1 and VEGFR2. Studies employing purified protein systems and cell-based bioassays demonstrated robust, picomolar-range inhibition of receptor activation and downstream signaling. This canonical mechanism explained the majority of therapeutic effects observed across disease models, including reduced endothelial cell migration, proliferation, and vascular permeability.

Non-Canonical Mechanisms and Their Context-Dependence

However, three distinct non-canonical mechanisms emerged that operated independently of or in addition to direct VEGFR inhibition:

First, aflibercept bound galectin-1 with higher affinity (KD = 23.68 nM) than VEGFR1-Fc or VEGFR2-Fc, neutralizing its angiogenic activity independently of VEGF-A. This mechanism appeared particularly relevant in PDR, where galectin-1 levels were elevated in vitreous independent of VEGF-A levels, and galectin-1 immunoreactivity co-localized with VEGFR2 in neovascular tissues. The N-glycosylation of aflibercept was essential for this galectin-1 binding, distinguishing it from the protein backbone-mediated VEGF binding.

Second, in PVR models, VEGF’s major contribution to vitreal bioactivity occurred via platelet-derived growth factor receptor α (PDGFRα) rather than canonical VEGFRs. VEGF acted noncanonically through PDGFRα to promote cell viability, enabling non-PDGF-driven activation of this receptor. Aflibercept’s neutralization of VEGF eliminated this PDGFRα-mediated bioactivity, explaining efficacy in a disease context where VEGFR signaling was not the primary driver.

Third, aflibercept’s VEGF/KDR inhibition triggered a compensatory increase in hypoxia-inducible factor-1α (HIF-1α) accumulation, leading to upregulation of angiopoietin-like 4 (ANGPTL4), a second angiogenic mediator. This countertherapeutic effect helped explain inadequate responses in some nvAMD patients, as ANGPTL4 expression increased despite VEGF suppression. The mechanism operated through KDR inhibition affecting HIF-1α stability, representing an unintended consequence of the primary therapeutic mechanism.

Indirect Effects on Additional Pathways

Beyond these non-canonical targets, aflibercept indirectly modulated several angiogenesis-related pathways. The drug suppressed angiopoietin-2 (ANG2) protein in vitreous and ANGPT2 mRNA in retinal tissue, even though aflibercept does not directly bind ANG2. This suppression likely occurred secondary to VEGF-induced vascular changes, as ANG2 is downstream of the angiogenic switch. Similarly, aflibercept reduced activation of mononuclear phagocytes via PlGF/VEGFR1 signaling in immune cells, affecting inflammatory pathways that contributed to CNV progression.

Integration and Clinical Implications

The narrow proteome changes observed in the porcine CRVO model, with only 21 proteins altered and minimal regulation of multiple signaling pathways, contrasted with the broader effects seen in other disease contexts. This heterogeneity reflected context-dependent activation of non-canonical mechanisms. In PDR with elevated galectin-1, the galectin-1-binding mechanism provided additional therapeutic value. In PVR driven by PDGFRα signaling, the ability to neutralize VEGF’s non-canonical PDGFRα activation proved critical. In treatment-resistant nvAMD, the HIF-1α/ANGPTL4 pathway undermined efficacy, suggesting combination approaches targeting both VEGF and HIF-1α might overcome resistance.

The 1:1 binding stoichiometry and occlusion of the heparin-binding site distinguished aflibercept from bevacizumab mechanistically, preventing formation of large immune complexes and avidity-driven Fc receptor interactions. This unique binding geometry contributed to the safety profile while maintaining therapeutic potency.

Human tissue analysis from PDR patients revealed that preoperative bevacizumab injection reduced VEGF-A but not galectin-1 levels, whereas aflibercept’s dual targeting of both factors suggested a mechanistic advantage in this specific context. The superior ANG2 suppression with aflibercept compared to ranibizumab further exemplified how binding properties (broader ligand specificity, tighter affinity, faster association) translated to differential effects on downstream pathways.

References

• Atsuhiro Kanda, K. Noda, W. Saito, S. Ishida (2015). Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy. Scientific Reports
• D. MacDonald, et al. (2016). Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes. Angiogenesis
• No authors found (2012). Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis
• H. Deissler, et al. (2014). Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells. Experimental Eye Research
• C. Lange, et al. (2023). Aflibercept Suppression of Angiopoietin-2 in a Rabbit Retinal Vascular Hyperpermeability Model. Translational Vision Science & Technology
• S. Pennock, et al. (2014). Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy. American Journal of Pathology
• G. Giurdanella, et al. (2015). Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway. Biochemical Pharmacology
• S. Crespo-Garcia, et al. (2017). Inhibition of Placenta Growth Factor Reduces Subretinal Mononuclear Phagocyte Accumulation in Choroidal Neovascularization. Investigative Ophthalmology and Visual Science
• D. Sharma, et al. (2024). VEGF inhibition increases expression of HIF-regulated angiogenic genes by the RPE limiting the response of wet AMD eyes to aflibercept. Proceedings of the National Academy of Sciences of the United States of America
• L. Cehofski, et al. (2022). Proteome Analysis of Aflibercept Intervention in Experimental Central Retinal Vein Occlusion. Molecules